Preferred therapies for neovascular age-related macular degeneration

Current Opinion in Ophthalmology

Volumn 22, Issue 3, 2011, Pages 199-204

  Chiang, Allen ^a   Regillo, Carl D ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b Mid Atlantic Retina   (United States)

Author keywords

bevacizumab; macular degeneration; neovascularization; ranibizumab; vascular endothelial growth factor

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN INHIBITOR; VERTEPORFIN;

ARTICLE; CLINICAL PRACTICE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; MULTICENTER STUDY (TOPIC); OPTICAL COHERENCE TOMOGRAPHY; PHASE 3 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA ANGIOGRAPHY; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; CLINICAL TRIALS AS TOPIC; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 79955053611     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e32834597d9     Document Type: Article

References (61)

1. Chakravarthy U, Augood C, Bentham GC, et al. Cigarette smoking and agerelated macular degeneration in the EUREYE study. Ophthalmology 2007; 114:1157-1163. (Pubitemid 46829372)
2. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA 2004; 291:1900-1901. (Pubitemid 38509505)
3. Arias E. United states life tables, 2009. Natl Vital Stat Rep 2010; 58:1-40.
4. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1991; 109:1220-1231.
5. Brown G, Brown MM. Let us wake the nation on the treatment for age-related macular degeneration. Curr Opin Ophthalmol 2010; 21:169-171.
6. Brown MM, Brown GC, Stein JD, et al. Age-related macular degeneration: economic burden and value-based medicine analysis. Can J Ophthalmol 2005; 40:277-287. (Pubitemid 40942254)
7. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669-676. (Pubitemid 36749215)
8. Kliffen M, Sharma HS, Mooy CM, et al. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 1997; 81:154-162. (Pubitemid 27092496)
9. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1432-1444. (Pubitemid 44511558)
10. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANC.H.OR study. Ophthalmology 2009; 116:57-65 e5.
11. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular agerelated macular degeneration. N Engl J Med 2006; 355:1419-1431. (Pubitemid 44511557)
12. Kaiser PK, Blodi BA, Shapiro H, Acharya NR. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007; 114:1868-1875.
13. Sadda SR, Stoller G, Boyer DS, et al. Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor study. Retina 2010; 30:1390-1399.
14. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006; 26:383-390. (Pubitemid 44197628)
15. Emerson MV, Lauer AK, Flaxel CJ, et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 2007; 27:439-444. (Pubitemid 46624283)
16. Pedersen R, Soliman W, Lund-Andersen H, Larsen M. Treatment of choroidal neovascularization using intravitreal bevacizumab. Acta Ophthalmol Scand 2007; 85:526-533. (Pubitemid 47163114)
17. Aggio FB, Farah ME, Silva WC, Melo GB. Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments. Graefes Arch Clin Exp Ophthalmol 2007; 245:215-220. (Pubitemid 46291451)
18. Chen E, Kaiser RS, Vander JF. Intravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration. Retina 2007; 27:445-450. (Pubitemid 46624284)
19. Cleary CA, Jungkim S, Ravikumar K, et al. Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results. Eye (Lond) 2008; 22:82-86.
20. Jonas JB, Libondi T, Ihloff AK, et al. Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type. Acta Ophthalmol Scand 2007; 85:563-565. (Pubitemid 47163119)
21. Yoganathan P, Deramo VA, Lai JC, et al. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina 2006; 26:994-998. (Pubitemid 44973217)
22. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113:363-72e5.
23. Bashshur ZF, Haddad ZA, Schakal A, et al. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol 2008; 145:249-256.
24. Weigert G, Michels S, Sacu S, et al. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. Br J Ophthalmol 2008; 92:356-360. (Pubitemid 351363530)
25. Lazic R, Gabric N. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007; 245:68-73. (Pubitemid 46766732)
26. Chen CY, Wong TY, Heriot WJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. Am J Ophthalmol 2007; 143:510-512.
27. Algvere PV, Steen B, Seregard S, Kvanta A. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. Acta Ophthalmol 2008; 86:482-489.
28. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan- American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008; 246:81-87. (Pubitemid 350167096)
29. Jyothi S, Chowdhury H, Elagouz M, Sivaprasad S. Intravitreal bevacizumab (Avastin) for age-related macular degeneration: a critical analysis of literature. Eye (Lond) 2010; 24:816-824.
30. Arevalo JF, Sanchez JG, Wu L, et al. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twentyfour months: the Pan-American Collaborative Retina Study. Ophthalmology 2010; 117:1974-1981; 81 e1.
31. Bashshur ZF, Haddad ZA, Schakal AR, et al. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study. Am J Ophthalmol 2009; 148:59-65el.
32. Tufail A, Patel PJ, Egan C, et al. Bevacizumab for neovascular age related macular degeneration (ABC trial): multicentre randomised double masked study. BMJ 2010; 340:c2459.
33. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, shamcontrolled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol 2008; 145:239-248.
34. Abraham P, Yue H, Wilson L. Randomized double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol 2010; 150:315 e1-324 e1.
35. Bolz M, Schmidt-Erfurth U. Ranibizumab EXCITE study: exploring the value of optical coherence tomography for the management of ranibizumab therapy in agerelated macular degeneration. In: 8th EURETINA Congress; Vienna; 2008 May.
36. Spaide R. Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol 2007; 143:679-680. (Pubitemid 46452536)
37. Brown DM, Regillo CD. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol 2007; 144:627-637.
38. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PRONTO study. Am J Ophthalmol 2009; 148:43 e1-58 e1.
39. Boyer DS, Heier JS, Brown DM, et al. A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009; 116:1731-1739.
40. Meyer CF, Eter N, Holz FG. Ranibizumab in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Interim results from the SUSTAIN trial (abstract). Invest Ophthalmol Vis Sci 2008:Eabstract 273.
41. Dadgostar H, Ventura AA, Chung JY, et al. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative agerelated macular degeneration. Ophthalmology 2009; 116:1740-1747.
42. Rothenbuehler SP, Waeber D, Brinkmann CK, et al. Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration. Am J Ophthalmol 2009; 147:831-837.
43. Cohen SY, Dubois L, Tadayoni R, et al. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. Am J Ophthalmol 2009; 148:409-413.
44. Gupta OP, Shienbaum G, Patel AH, et al. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology 2010; 117:2134-2140.
45. Shienbaum G, Gupta OP, Fecarotta C, et al. Management of neovascular agerelated macular degeneration using bevacizumab with the treat and extend regimen: clinical results and economic impact. In: ARVO; Fort Lauderdale, Florida; 2010.
46. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 2004; 122:598-614. (Pubitemid 38456297)
47. Kent D, Sheridan C. Choroidal neovascularization: a wound healing perspective. Mol Vis 2003; 9:747-755. (Pubitemid 38097640)
48. Bradley J, Ju M, Robinson GS. Combination therapy for the treatment of ocular neovascularization. Angiogenesis 2007; 10:141-148. (Pubitemid 46440632)
49. Bergers G, Song S, Meyer-Morse N, et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003; 111:1287-1295. (Pubitemid 36554699)
50. Cruess AF, Zlateva G, Pleil AM, Wirostko B. Photodynamic therapy with verteporfin in age-related macular degeneration: a systematic review of efficacy, safety, treatment modifications and pharmacoeconomic properties. Acta Ophthalmol 2009; 87:118-132.
51. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization -verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001; 131:541-560.
52. Azab M, Benchaboune M, Blinder KJ, et al. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials - treatment of Age-Related Macular Degeneration with Photodynamic Therapy and Verteporfin in Photodynamic Therapy Study Report no. 4. Retina 2004; 24:1-12.
53. Azab M, Boyer DS, Bressler NM, et al. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 2005; 123:448-457. (Pubitemid 40489914)
54. Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, et al. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003; 44:4473-4480. (Pubitemid 37186285)
55. Wan MJ, Hooper PL, Sheidow TG. Combination therapy in exudative agerelated macular degeneration: visual outcomes following combined treatment with photodynamic therapy and intravitreal bevacizumab. Can J Ophthalmol 2010; 45:375-380.
56. Costagliola C, Romano MR, Rinaldi M, et al. Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Br J Ophthalmol 2010; 94:180-184.
57. Potter MJ, Claudio CC, Szabo SM. A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: the VIA study. Br J Ophthalmol 2010; 94:174-179.
58. Lim JY, Lee SY, Kim JG, et al. Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50 years or older: 1-year results of a prospective clinical study. Acta Ophthalmol 2010 [Epub ahead of print].
59. Kaiser PK. Combination therapy with verteporfin and anti-VEGF agents in neovascular age-related macular degeneration: where do we stand? Br J Ophthalmol 2010; 94:143-145.
60. Bayer and Regeneron report positive top-line results of two phase 3 studies with VEGF Trap-Eye in wet age-related macular degeneration; 22 November 2010. http://newsroom.regeneron.com/releasedetail.cfm?ReleaseID=532099. [Accessed 1 December 2010].
61. Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2010; 94:2-13